AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Monday 2 November 2026
News from the 24 hours to Monday morning, 2 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by third-quarter results that beat expectations, with oncology gains and a share price jump of around 7%. Positive analyst and trial news added support, while a report on a record pay package for the chief executive was a minor negative.
What drove it
- Q3 earnings beat
- oncology gains
- share price rally
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Tue 27 Oct | +9.2 | 35 |
| Wed 28 Oct | +7.5 | 33 |
| Thu 29 Oct | +2.8 | 13 |
| Fri 30 Oct | +6.3 | 13 |
| Sat 31 Oct | +8.7 | 78 |
| Sun 1 Nov | +6.3 | 8 |
| Mon 2 Nov | +9.2 | 15 |
| Tue 3 Nov | +7.5 | 28 |
7 stories · 15 headlines · strongest first
Pharma and healthcare on 2 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| AstraZeneca Q3 results and $1.5bn savings plan +7.19 headlines today · 80 in all, since 31 October · Coverage of the Q3 beat, oncology growth, share rise and cost cuts. | ||
| +10.0 | Quarterly results above forecasts and shares up sharply. | |
| +10.0 | Shares up on cancer successes and better-than-expected earnings. | |
| +10.0 | Share rise driven by cancer progress and quarterly outperformance. | |
| +10.0 | Results presentation shows cancer drugs driving outperformance and healthy pipeline. | |
| +10.0 | Shares surged on strong cancer drug performance. | |
| +9.2 | Recap of quarterly revenue growth, oncology progress and planned savings. | |
| +7.5 | Investor commentary highlights positives for the longer term. | |
| +6.3 | Strong share jump, though technical indicator suggests stretched valuation. | |
| +5.0 | Shares rose strongly ahead of an investor roadshow. | |
| AstraZeneca medicines used together lengthen survival in lung cancer +5.81 headline today · 5 in all · A drug combination extended survival in lung cancer. | ||
| +10.0 | Combination therapy shows improved patient survival in lung cancer. | |
| RBC rates AstraZeneca Buy +7.01 headline today · RBC maintains a Buy rating. | ||
| +7.0 | Broker analyst recommends buying the shares. | |
| HUTCHMED filings accepted for Orpathys plus Tagrisso +5.81 headline today · Regulatory filings for a lung cancer combination were accepted in Europe and Japan. | ||
| +5.8 | Partner's regulatory filings accepted for combination involving its Tagrisso drug. | |
| AstraZeneca chief is aiming for a record £28m remuneration package −3.31 headline today · Pascal Soriot's potential record pay package is reported. | ||
| −3.3 | Record executive pay package may attract shareholder and public criticism. | |
| AstraZeneca gained 1.6% among Nordic shares quoted in North America +3.31 headline today · A market note on AstraZeneca's share move. | ||
| +3.3 | Modest share price gain noted in market roundup. | |
| Week's healthcare news features AstraZeneca +0.81 headline today · A weekly roundup features AstraZeneca and others. | ||
| +0.8 | Weekly sector roundup mentioning it among several companies. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.